This suggests that colon tumors with the particular genetic profile of RKO (BRAF mutated) may benefit most from the potential applications of VPE in anti-colon cancer strategies than KRAS mutated HCT116-like tumors. The gene discussed is BRAF; the disease is malignant colon neoplasm.